Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Koychev I, Reid G, Nguyen M, Mentz RJ, Joyce D, Shah SH, Holman RR.
Alzheimers Res Ther. 2024 Oct 2;16(1):212. doi: 10.1186/s13195-024-01573-x.
Analysis of early effects of human APOE isoforms on Alzheimer's disease and type III hyperlipoproteinemia pathways using knock-in rat models with humanized APP and APOE.
Yesiltepe M, Yin T, Tambini M, Bao H, Pan M, d'Abramo C, Giliberto L, Han X, D'Adamio L.
Cell Commun Signal. 2024 Sep 27;22(1):458. doi: 10.1186/s12964-024-01832-2.
The autophagy adaptor TRIAD3A promotes tau fibrillation by nested phase separation.
Zhou J, Chuang Y', Redding-Ochoa J, Zhang R, Platero AJ, Barrett AH, Troncoso JC, Worley PF, Zhang W.
Nat Cell Biol. 2024 Aug;26(8):1274-1286. doi: 10.1038/s41556-024-01461-4. Epub 2024 Jul 15.
Alzheimer's Disease and (Phyto) Estrogen Treatment: Modification of Effects by Age, Type of Treatment, and Duration of Use.
Kuck MJ, Begde A, Hawkins K, Hogervorst E.
J Alzheimers Dis. 2024;101(s1):S217-S234. doi: 10.3233/JAD-231415.
Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.
Hartley SL, Fleming V, Schworer EK, Peven J, Handen BL, Krinsky-McHale S, Hom C, Lee L, Tudorascu DL, Laymon C, Minhas D, Luo W, Cohen A, Zaman S, Ances BM, Mapstone M, Head E, Lai F, Rosas HD, Klunk W, Christian B; Alzheimer Biomarker Consortium-Down Syndrome.
J Alzheimers Dis. 2023;95(1):213-225. doi: 10.3233/JAD-230200.
Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review.
Valletta M, Canevelli M, Gasparini F, Buscarnera S, Salzillo M, Triolo F, Calderón-Larrañaga A, Marengoni A, Vetrano DL, Grande G.
Eur Geriatr Med. 2025 Aug;16(4):1121-1136. doi: 10.1007/s41999-025-01222-y. Epub 2025 May 20.
Allele-specific analysis reveals exon- and cell-type-specific regulatory effects of Alzheimer's disease-associated genetic variants.
He L, Loika Y, Kulminski AM.
Transl Psychiatry. 2022 Apr 18;12(1):163. doi: 10.1038/s41398-022-01913-1.
gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
Schultz SA, Liu L, Schultz AP, Fitzpatrick CD, Levin R, Bellier JP, Shirzadi Z, Joseph-Mathurin N, Chen CD, Benzinger TLS, Day GS, Farlow MR, Gordon BA, Hassenstab JJ, Jack CR Jr, Jucker M, Karch CM, Lee JH, Levin J, Perrin RJ, Schofield PR, Xiong C, Johnson KA, McDade E, Bateman RJ, Sperling RA, Selkoe DJ, Chhatwal JP; Dominantly Inherited Alzheimer Network.
Lancet Neurol. 2024 Sep;23(9):913-924. doi: 10.1016/S1474-4422(24)00236-9. Epub 2024 Jul 26.
Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis.
Jiang C, Qi J, Zou H, Lopez O, Xie XQ, Xue Y.
J Alzheimers Dis. 2025 Oct;107(3):1294-1303. doi: 10.1177/13872877251365662. Epub 2025 Aug 25.
Accelerated amyloid angiopathy and related vascular alterations in a mixed murine model of Alzheimer s disease and type two diabetes.
Vargas-Soria M, Ramos-Rodriguez JJ, Del Marco A, Hierro-Bujalance C, Carranza-Naval MJ, Calvo-Rodriguez M, van Veluw SJ, Stitt AW, Simó R, Bacskai BJ, Infante-Garcia C, Garcia-Alloza M.
Fluids Barriers CNS. 2022 Nov 7;19(1):88. doi: 10.1186/s12987-022-00380-6.
